Mallinckrodt Vision For Growth Emphasizes Acthar, Ofirmev
The specialty pharma laid out plans for driving future growth after completing two acquisitions earlier this year. Two of the key drivers will be drugs acquired in those deals – along with more business development.
You may also be interested in...
Mallinckrodt's FTC Settlement Seems A Blip For Acthar Blockbuster
Company anticipates steady sales of its blockbuster treatment for infantile spasms and other severe conditions for many years, despite agreement to out-license a potential competitor as part of settlement with US trade commission. Settlement resolving investigation into earlier Questcor acquisition also includes $100m fine.
Questcor Expansion Strategy Pays Off For Acthar
Questcor has successfully revived a decades-old product by raising the drug’s price, securing a new approval in a niche orphan indication in infants and making a commercial push in areas like multiple sclerosis and rheumatoid arthritis.
Cadence Builds Case For Branded IV Acetaminophen; Can It Reduce Opioid Use?
After rebounding from regulatory setbacks, Cadence Pharmaceuticals Inc. intravenous acetaminophen Ofirmev has been approved by FDA with a label many analysts praise as broad and positive.